Enzo Biochem Inc. (ENZ) Announces Earnings Results
Enzo Biochem Inc. (NYSE:ENZ) announced its quarterly earnings results on Thursday. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. Enzo Biochem had a net margin of 44.06% and a negative return on equity of 18.54%. The firm earned $26.60 million during the quarter. During the same period last year, the company posted ($0.06) earnings per share.
Shares of Enzo Biochem (NYSE:ENZ) opened at 5.63 on Monday. The stock has a market capitalization of $260.47 million, a PE ratio of 14.74 and a beta of 1.50. Enzo Biochem has a 12 month low of $3.48 and a 12 month high of $7.00. The company’s 50-day moving average is $5.34 and its 200-day moving average is $5.69.
Separately, Zacks Investment Research cut shares of Enzo Biochem from a “buy” rating to a “hold” rating in a research report on Tuesday, August 9th.
Several institutional investors have recently added to or reduced their stakes in ENZ. A.R.T. Advisors LLC acquired a new position in Enzo Biochem during the second quarter worth approximately $101,000. Cubist Systematic Strategies LLC acquired a new position in Enzo Biochem during the second quarter worth approximately $111,000. BlackRock Advisors LLC increased its position in Enzo Biochem by 148.5% in the second quarter. BlackRock Advisors LLC now owns 19,949 shares of the company’s stock worth $119,000 after buying an additional 11,921 shares during the last quarter. KBC Group NV increased its position in Enzo Biochem by 207.8% in the second quarter. KBC Group NV now owns 20,551 shares of the company’s stock worth $123,000 after buying an additional 13,875 shares during the last quarter. Finally, American International Group Inc. increased its position in Enzo Biochem by 2,184.6% in the second quarter. American International Group Inc. now owns 22,846 shares of the company’s stock worth $136,000 after buying an additional 21,846 shares during the last quarter. 53.29% of the stock is owned by institutional investors.
About Enzo Biochem
Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.
Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.